Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma

Author：            

Publisher： Spandidos Publications

ISSN： 1107-3756

Source： International Journal of Molecular Medicine, Vol.31, Iss.2, 2013-01, pp. : 339-346

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor

By  

Oncology Research and Treatment, Vol. 33, Iss. 7, 2010-06 ,pp. : 401-402

Karger

Access to resources Recommend Favorite

Histone deacetylase inhibitor for NUT midline carcinoma

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 4, 2015-04 ,pp. : 715-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy

By  

Oncology, Vol. 85, Iss. 1, 2013-06 ,pp. : 8-13

Karger

Access to resources Recommend Favorite

Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells

By  

THE PROSTATE, Vol. 75, Iss. 7, 2015-05 ,pp. : 693-705

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells

By              

International Journal of Molecular Medicine, Vol. 31, Iss. 4, 2013-01 ,pp. : 904-912

Spandidos Publications

Access to resources Recommend Favorite